Optomed Oyj Q4 2025 Financial Results

Optomed Oyj released its year‑end financial statements for the period January–December 2025 on 10 February 2026. The company’s reported revenue for the quarter was €4.8 million, a figure that aligns with market expectations.

Profitability

Operating profit for the quarter was ‑€1.3 million. This loss is attributed to a one‑off cost that affected the EBIT margin. The negative EBIT is below analysts’ forecasts and represents a decline in profitability relative to the previous quarter.

Guidance

Optomed has issued cautious outlooks for the coming year. The company acknowledges the impact of the one‑off expense and indicates that future guidance will reflect this adjustment.

Market Reaction

The announcement coincided with a broader decline in the Helsinki market, where the benchmark index fell 0.1 percent to 12 818,76 points. Optomed’s shares experienced a downward movement in line with the general market trend, reflecting investor concerns over the operating loss and the company’s cautious guidance.

Analyst Commentary

Redeye analysts highlighted that while sales were in line with projections, the EBIT figure was lower than expected due to the one‑off cost. The overall sentiment is that the company’s device segment remains supportive, but the temporary expense has dampened short‑term earnings expectations.

Summary

  • Revenue: €4.8 M (in line with expectations)
  • EBIT: ‑€1.3 M (below expectations, affected by a one‑off cost)
  • Guidance: Cautious, reflecting the impact of the exceptional expense
  • Market Impact: Shares fell in a broader market decline on 10 February 2026.